These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10864147)

  • 1. Characterization of histamine release induced by fluoroquinolone antibacterial agents in-vivo and in-vitro.
    Mori K; Maru C; Takasuna K
    J Pharm Pharmacol; 2000 May; 52(5):577-84. PubMed ID: 10864147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential response of mast cells separated from various organs and basophils of dogs to the fluoroquinolone antimicrobial levofloxacin.
    Mori K; Shibano M; Satoh H; Takasuna K; Furuhama K
    Arch Toxicol; 2001 Jun; 75(4):227-33. PubMed ID: 11482521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histamine-releasing properties of T-3762, a novel fluoroquinolone antimicrobial agent in intravenous use. II. Dermovascular permeability-increasing effect and action on peritoneal mast cells.
    Furuhata K; Fukuda Y; Soumi K; Arai H; Watanabe Y; Narita H
    Biol Pharm Bull; 1998 May; 21(5):461-4. PubMed ID: 9635500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of histamine release induced by levofloxacin, a fluoroquinolone antibacterial agent.
    Mori K; Maru C; Takasuna K; Furuhama K
    Eur J Pharmacol; 2000 Apr; 394(1):51-5. PubMed ID: 10771034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine-releasing properties of T-3762, a novel fluoroquinolone antimicrobial agent in intravenous use. I. Effects of doses and infusion rate on blood pressure, heart rate and plasma histamine concentration.
    Furuhata K; Hayakawa H; Soumi K; Arai H; Watanabe Y; Narita H
    Biol Pharm Bull; 1998 May; 21(5):456-60. PubMed ID: 9635499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of levofloxacin and ciprofloxacin injection on permeability of the tail vein in mice and skin microvasculature in rats.
    Yoshida M; Takayama S; Kato M
    Int J Tissue React; 1994; 16(3):105-12. PubMed ID: 7852031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
    Drugeon HB; Juvin ME; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the histamine-releasing activity of cremophor E1 and some of its derivatives in two experimental models: the in vivo anaesthetized dog and in vitro rat peritoneal mast cells.
    Ennis M; Lorenz W; Kapp B; Lüben L; Schmal A
    Agents Actions; 1985 Apr; 16(3-4):265-8. PubMed ID: 2409775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats.
    Ogawa K; Nabe T; Yamamura H; Kohno S
    Eur J Pharmacol; 1999 Jun; 374(2):285-91. PubMed ID: 10422770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
    George J; Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis.
    Kitzis MD; Goldstein FW; Miegi M; Acar JF
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():21-6. PubMed ID: 10404333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of levofloxacin and ciprofloxacin against bacterial isolates from neutropenic patients.
    Di Bonaventura G; D'Antonio D; Catamo G; D'Ercole S; Piccolomini R
    Chemotherapy; 2002 Jul; 48(3):134-7. PubMed ID: 12138329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R; Andrews JM
    J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Frémaux A; Sissia G; Geslin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model.
    Aeschlimann JR; Kaatz GW; Rybak MJ
    J Antimicrob Chemother; 1999 Sep; 44(3):343-9. PubMed ID: 10511401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
    MacGowan AP; Wootton M; Holt HA
    J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histamine release from mast cells of various species induced by histamine releasing factor from human lymphocytes.
    Brzezińska-Błaszczyk E; Czuwaj M; Kuna P
    Agents Actions; 1987 Jun; 21(1-2):26-31. PubMed ID: 2442980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.